Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Disufenton sodium (NXY-059), a new-type nitrone, exhibits potently neuroprotective effects.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 37.00 | |
10 mg | In stock | $ 60.00 | |
25 mg | In stock | $ 118.00 | |
50 mg | In stock | $ 217.00 | |
100 mg | In stock | $ 397.00 | |
200 mg | In stock | $ 582.00 | |
500 mg | In stock | $ 913.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 40.00 |
Description | Disufenton sodium (NXY-059), a new-type nitrone, exhibits potently neuroprotective effects. |
In vitro | NXY-059 is more soluble than the spin trapping agent α-phenyl-N-tert-butyl nitrone (PBN). [1] In an in vitro blood-brain barrier (BBB) model, 250 mM of NXY-059 administered at the onset or up to 4 h after oxygen glucose deprivation (OGD) produces a significant reduction in the increased BBB permeability caused by OGD. Furthermore, OGD produces a huge influx of tissue plasminogen activator across the BBB, which is substantially reduced by NXY-059. [2] |
In vivo | NXY-059 reduces infarct volume in rats subjected to 2 hours of middle cerebral artery occlusion in a dose-dependent manner. At equimolar doses (3.0 mg/kg for NXY-059 and 1.4 mg/kg for PBN), NXY-059 is more efficacious than PBN. Similar results are obtained when a recovery period of 7 days is allowed. The window of therapeutic opportunity for NXY-059 is 3 to 6 hours after the start of recirculation. [1] NXY-059, a free radical-trapping agent, has a substantial protective effect, lessening the disability caused by an experimentally induced stroke in a primate species. NXY-059 treatment reduces the overall amount of brain damage by >50% of saline-treatment values, with similar levels of protection afforded to both white and gray matter. [3] Treatment with NXY-059 (50 mg/kg subcutaneous plus 8.8 mg/kg/h for 3 days subcutaneous delivered via implanted osmotic pumps) significantly decreases neurological impairment following intracerebral hemorrhage in rat, and reduces the neutrophil infiltrate observed 48 hours post-hemorrhage in the vicinity of the hematoma, and the number of TUNEL-positive cells 48 hours post-hemorrhage at the hematoma margin. [4] |
Synonyms | Cerovive, NXY059, OKN007, NXY-059, NXY 059 |
Molecular Weight | 381.33 |
Formula | C11H13NNa2O7S2 |
CAS No. | 168021-79-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 70 mg/mL (183.6 mM)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 71 mg/mL (186.2 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Disufenton sodium 168021-79-2 Immunology/Inflammation Metabolism NF-Κb Reactive Oxygen Species Inhibitor Cerovive OKN-007 OKN 007 inhibit NXY059 Disufenton OKN007 NXY-059 NXY 059 inhibitor